Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186818 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
A Phase 3 study of Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
- 20
- Study locations
NCT05186818 is a Phase 3 study of Obstructive Hypertrophic Cardiomyopathy (oHCM) that has completed, run by Cytokinetics. The registered enrollment target is 282 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT05186818, a Phase 3 study of Obstructive Hypertrophic Cardiomyopathy (oHCM), has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
Conditions Studied
Interventions
- DRUG Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- DRUG Placebo to match aficamten
Study Locations (20)
California
- UC San Diego Health - Sulpizio Cardiovascular Center - La Jolla
- Cedars-Sinai Medical Center - Smidt Heart Institute Clinic - Los Angeles
- University of California San Francisco - San Francisco
- Stanford University Hospital - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Lahey Hospital & Medical Center - Burlington
Connecticut
- Yale School of Medicine - New Haven
- Yale University School of Medicine - New Haven
Florida
- Holy Cross Hospital / Cardiology Associates - Fort Lauderdale
- Mayo Clinic Florida - Jacksonville
Georgia
- Emory Clinic - Atlanta
- Piedmont Fayette Hospital - Fayetteville
Maryland
- MedStar Medical Group Cardiology at Union Memorial - Baltimore
- Medstar Franklin Square Medical Center - Baltimore
Alaska
- Alaska Heart and Vascular Institute - Anchorage
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05186818
The ClinicalTrials.gov registry entry for NCT05186818 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obstructive Hypertrophic Cardiomyopathy (oHCM) appearing as the primary indexed condition, and to 2 interventions - of which Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) is the first listed.
NCT05186818 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Massachusetts, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05186818 about?
NCT05186818 is a clinical study titled "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM". The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
What is the current status of trial NCT05186818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2022-02-01. Estimated completion is 2023-12-18.
What conditions does trial NCT05186818 study?
This clinical trial studies the following conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM).
What interventions are being tested in trial NCT05186818?
The interventions under investigation include: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) (DRUG), Placebo to match aficamten (DRUG).
Who is sponsoring clinical trial NCT05186818?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186818 being conducted?
This trial has 20 study locations across Alaska, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.